Goldline Pharmaceutical board to consider FY26 results on June 9

0 min read     Updated on 02 Jun 2026, 04:16 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Goldline Pharmaceutical Limited will hold a board meeting on June 09, 2026, to consider standalone audited financial results for the half-year and year ended March 31, 2026. The meeting will take place at the company's registered office in Nagpur.

powered bylight_fuzz_icon
41942790

*this image is generated using AI for illustrative purposes only.

Goldline Pharmaceutical Limited has scheduled a board meeting on June 09, 2026, to consider and approve the standalone audited financial results for the half-year and year ended March 31, 2026. The meeting will be conducted at the company's registered office located at 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, India, 440015.

The agenda includes a review of the financial results prepared in compliance with applicable accounting standards, along with the statement of assets and liabilities. This disclosure is made pursuant to Regulation 29 (1) (a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

Parameter Details
Date June 09, 2026
Location Registered Office, Nagpur
Purpose Financial Results for half-year and year ended March 31, 2026

Ruchi Sanket Modi, Company Secretary cum Compliance Officer, signed the intimation on behalf of goldline pharmaceutical . The outcome of the meeting will be filed separately with the exchanges.

Historical Stock Returns for Goldline Pharmaceutical

1 Day5 Days1 Month6 Months1 Year5 Years
-4.19%-4.67%-22.32%-22.32%-22.32%-22.32%

What market expectations exist for Goldline Pharmaceutical's year-end profitability given the upcoming financial release?

How might the approval of these audited results influence the company's stock liquidity and investor sentiment?

Are there any anticipated strategic shifts or capital allocation plans likely to be announced alongside the financial results?

Goldline Pharmaceutical
View Company Insights
View All News
like20
dislike
1 Year Returns:-22.32%